Brainomix, a pioneer in AI-powered imaging, is raising the bar for stroke diagnostics with the launch of its Brainomix 360 Next Generation platform. The announcement came at the International Stroke Conference (ISC) in New Orleans, February 4–6, 2026, and signals a major step forward in using routine CT scans to guide urgent treatment decisions.
The platform’s standout feature is its first-of-its-kind net water uptake (NWU) analysis, fully automated and regulatory cleared, which converts routine non-contrast CT (NCCT) scans into actionable, percentage-based insights. Clinicians can now extract expert-level stroke injury information without additional imaging, potentially improving both treatment selection and inter-hospital transfer decisions.
Award-Winning Design Meets AI Precision
Beyond technical upgrades, Brainomix 360 Next Gen recently earned a Red Dot Design Award, recognized for exceptional usability, safety, and innovation. Among 20,000 submissions from 60 countries, Brainomix joins household names like Apple, Sony, and Samsung, highlighting the growing convergence of medical imaging and user-centric design. The platform also offers enhanced DICOM viewing and AI-driven, patient-specific insights, helping radiologists and neurologists make faster, more confident decisions.
Dr. George Harston, Brainomix’s Chief Medical and Innovation Officer, emphasized the clinical impact: “Automated NWU output complements our existing ischemic core and e-ASPECTS features, providing deeper insights from routine CT scans. In severe strokes, where treatment uncertainty can cost lives, this innovation can boost physician confidence and improve patient outcomes.”
Evidence-Based Impact
Brainomix isn’t just talking the talk. The company presented five abstracts at ISC, three of which earned the Paul Dudley White International Scholar Award for top-ranked submissions. Key findings include:
- Cost-effectiveness analysis: Widespread adoption of Brainomix 360 Stroke could increase thrombolysis and thrombectomy rates, improve long-term outcomes, and generate a net monetary benefit.
- Validation of imaging foundation models: Automates follow-up infarct volume (FIV) segmentation.
- Prospective performance validation: Demonstrates efficacy of Brainomix 360 Triage LVO.
- Collateral circulation insights: Evaluates impact on inter-hospital stroke transfers.
- Stroke mimic detection: Introduces novel approaches for challenging differential diagnoses.
These studies underscore Brainomix’s ongoing commitment to clinically validated AI that integrates seamlessly into hospital workflows, potentially reshaping how stroke care is delivered worldwide.
Why It Matters
Stroke remains a leading cause of disability and death, with treatment often delayed by imaging uncertainty. Brainomix 360 Next Gen leverages readily available NCCT scans to bridge that gap, offering hospitals a scalable, evidence-backed tool to enhance patient care. Its combination of award-winning design, automated AI insights, and regulatory clearance positions Brainomix as a clear contender in the competitive AI imaging space, alongside rivals such as Viz.ai and RapidAI.
As hospitals increasingly adopt AI to streamline acute care, platforms like Brainomix 360 could define the next generation of stroke diagnostics, delivering smarter, faster, and safer clinical decisions.
Power Tomorrow’s Intelligence — Build It with TechEdgeAI
